|
Home Page
About Us
Investors
Inventors
Justin M. Balko, Pharm.D., Ph.D.
E. Penni Black, Ph.D.
Albert R. Cunningham, Ph.D.
Robert Falk, M.D.
George N. Hajishengallis, D.D.S., Ph.D.
Ted Kalbfleisch, Ph.D.
Y. James Kang, Ph.D.
Claudio Maldonado, Ph.D.
Gustavo A. Perez-Abadia, M.D.
William Pierce, Ph.D.
Norman D. Radtke, M.D.
Fred J. Roisen, Ph.D.
Haval Shirwan, Ph.D.
Audra Stinchcomb, Ph.D.
Roland Valdes, Jr., Ph.D.
Portfolio
Contact Us
Privacy Policy
|
|
|
|
Inventors - Haval Shirwan, Ph.D.
|
|
Haval Shirwan, Ph.D., ApoImmune
Haval Shirwan, Ph.D. is founder and chief scientific officer of ApoImmune. He is professor in the Department of Microbiology and Immunology at the University of Louisville, and is director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics at UofL. He also holds the Hamilton Chair in Autoimmune Disease and is a University Scholar at the School of Medicine.
Dr. Shirwan investigated the molecular basis of the effects interferons on the replication of viruses during his graduate studies at the University of California, Santa Barbara. His postdoctoral work at the California Institute of Technology dealt with the structure and function of major histocompatibility complex antigens. He was recruited from Caltech to start the Molecular Immunology Program at Cedars/Sinai Medical Center in Los Angeles with a focus on transplantation immunology. After a brief tenure at the Alleghany University of Health Sciences in Philadelphia, PA, Dr. Shirwan joined the faculty of the University of Louisville in 1998.
In recent years, Dr. Shirwan has focused on translational research and pioneered the ProtEx technology, ApoImmune's platform technology, as a safe, efficient, and practical alternative to DNA-based immune gene therapy for immunomodulation.
Dr. Shirwan has served on numerous study sections for national and international funding agencies, including the National Institutes of Health, the Veteran's Administration, The U.S.-Israel Binational Science Foundation, Israel Science Foundation, American Heart Association, Wellcome Trust, and Philip Morris USA Inc. He has also served on the Editorial Board of the journal Graft, was Section Editor for Current Opinion in Organ Transplantation, and an ad hoc reviewer for numerous scientific journals.
|
|
|
